# OnCo record copanlisib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/copanlisib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "copanlisib" ;
  schema:name "Copanlisib"@en ;
  schema:description "Copanlisib is an intravenous PI3K inhibitor for relapsed follicular lymphoma, approved in 2017 and withdrawn in 2023 when its confirmatory trial failed."@en ;
  schema:url <https://onco.cc/drugs/copanlisib/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Copanlisib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q19903876> ;
  schema:citation <https://en.wikipedia.org/wiki/Copanlisib> ;
  onco:status "withdrawn" ;
  onco:tag "gap-fill" ;
  onco:modality "Intravenous pan-class I PI3K inhibitor (α/δ predominant)" ;
  schema:alternateName "Aliqopa" ;
  onco:approval "US 2017: Relapsed follicular lymphoma after ≥2 therapies" ;
  onco:acceleratedApproval "US 2017-09-14: Treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies" ;
  onco:cancers <https://onco.cc/cancers/follicular-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/pik3ca/> ;
  onco:companies <https://onco.cc/companies/bayer/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/> .